Arix Bioscience PLC: Harpoon Therapeutics announces closing of public offering

DJ Harpoon announces closing of public offering

Arix Bioscience PLC (ARIX) 
Harpoon announces closing of public offering 
 
12-Jan-2021 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
                            Arix Bioscience plc 
 
                Harpoon announces closing of public offering 
 
  LONDON, 12 January 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global 
   venture capital company focused on investing in and building breakthrough 
  biotech companies, notes that its portfolio company, Harpoon Therapeutics, 
            Inc. ("Harpoon", Nasdaq: HARP), has announced the closing of its 
 underwritten public offering of 6,764,704 shares of its common stock, which 
  includes 882,352 shares sold upon the underwriters' full exercise of their 
 option to purchase additional shares, resulting in aggregate gross proceeds 
of approximately $115.0 million, before deducting underwriting discounts and 
          commissions and offering expenses payable by Harpoon Therapeutics. 
 
  Following the offering, Arix retains a stake of 6.9% in Harpoon, amounting 
                                        to 2,208,667 shares of common stock. 
 
                    The announcement can be accessed on Harpoon's website at 
https://ir.harpoontx.com/news-releases [1] and full text of the announcement 
                                            from Harpoon is contained below. 
 
                                   [ENDS] 
 
                                                                   Enquiries 
 
                               For more information on Arix, please contact: 
 
                                                         Arix Bioscience plc 
 
                                 Charlotte Parry, Head of Investor Relations 
 
                                                         [phone] 
 
                                                [e-mail] 
 
                                            Optimum Strategic Communications 
 
                                Supriya Mathur, Shabnam Bashir, Manel Mateus 
 
                                                         [phone] 
 
                                               [e-mail] 
 
                                                   About Arix Bioscience plc 
 
Arix Bioscience plc is a global venture capital company focused on investing 
 in and building breakthrough biotech companies around cutting-edge advances 
                                                           in life sciences. 
 
      We collaborate with exceptional entrepreneurs and provide the capital, 
 expertise and global networks to help accelerate their ideas into important 
 new treatments for patients. As a listed company, we are able to bring this 
      exciting growth phase of our industry to a broader range of investors. 
 
               For more information please visit: www.arixbioscience.com [2] 
 
*Harpoon Therapeutics Announces Closing of Public Offering of Common Stock* 
 
Underwriters Fully Exercise Option to Purchase Additional Shares 
 
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 -- Harpoon Therapeutics, Inc. 
(Nasdaq: HARP) announced today the closing of its underwritten public 
offering of 6,764,704 shares of its common stock, which includes 882,352 
shares sold upon the underwriters' full exercise of their option to purchase 
additional shares, resulting in aggregate gross proceeds of approximately 
$115.0 million, before deducting underwriting discounts and commissions and 
offering expenses payable by Harpoon Therapeutics. 
 
SVB Leerink and Piper Sandler acted as joint bookrunning managers for the 
offering. Baird and Truist Securities acted as co-lead managers for the 
offering. Roth Capital Partners acted as co-manager for the offering. 
 
The shares of common stock were offered pursuant to a "shelf" registration 
statement previously filed with and declared effective by the Securities and 
Exchange Commission (SEC). The offering is being made only by means of a 
prospectus supplement and accompanying prospectus, copies of which may be 
obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal 
Street, 37th Floor, Boston, MA 02110, by telephone at [phone], ext. 
6132 or by email at [e-mail] or Piper Sandler & Co., 
Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 
55402, by telephone at [phone] or by email at [e-mail]. 
 
This press release shall not constitute an offer to sell, or a solicitation 
of an offer to buy, nor shall there be any sale of these securities in any 
state or jurisdiction in which such offer, solicitation or sale would be 
unlawful prior to registration or qualification under the securities laws of 
any such state or jurisdiction. Any offer, if at all, will be made only by 
means of a prospectus supplement and accompanying prospectus, which are a 
part of the effective registration statement. 
 
Contacts: 
Harpoon Therapeutics, Inc. 
Georgia Erbez 
Chief Financial Officer 
650-443-7400 
[e-mail] 
 
Westwicke ICR 
Robert H. Uhl 
Managing Director 
858-356-5932 
[e-mail] 
 
ISIN:           GB00BD045071 
Category Code:  MSCU 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be 
                disclosed under the laws of a Member State 
Sequence No.:   91241 
EQS News ID:    1159934 
 
End of Announcement EQS News Service 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=6b747ef884586fd08f9b1bf9f3b4700a&application_id=1159934&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1159934&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

January 12, 2021 02:00 ET (07:00 GMT)